VTCN1 and breast carcinoma: Anti-B7H4/CD3 bsAbs applied in a breast cancer humanised mouse model led to immediate and strong antitumour activity tumours and CD8 and granzyme B+ CTL infiltration into the tumour, and there were no adverse effects after long-term observation [152].